Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
[P1]	O
plitidepsin	O
[P2]	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
IvanSpicka	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
[P1]	O
combination	O
with	O
dexamethasone	O
[P2]	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
IvanSpicka	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
[P1]	O
dexamethasone	O
alone	O
[P2]	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
IvanSpicka	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
[P1]	O
plitidepsin	O
[P2]	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
IvanSpicka	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
[P1]	O
combination	O
with	O
dexamethasone	O
[P2]	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
IvanSpicka	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
[P1]	O
dexamethasone	O
alone	O
[P2]	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
IvanSpicka	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
[P1]	O
plitidepsin	O
[P2]	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
[P1]	O
combination	O
with	O
dexamethasone	O
[P2]	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
[P1]	O
dexamethasone	O
alone	O
[P2]	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
[P1]	O
plitidepsin	O
[P2]	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
IvanSpicka	O
Department	O
of	O
Medicine	O
Faculty	O
of	O
Medicine	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
[P1]	O
dexamethasone	O
[P2]	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
IvanSpicka	O
Department	O
of	O
Medicine	O
Faculty	O
of	O
Medicine	O

Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
[P1]	O
dexamethasone	O
[P2]	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
IvanSpicka	O
Department	O
of	O
Medicine	O
Faculty	O
of	O
Medicine	O

Spain	O
Paseo	O
de	O
San	O
Vicente	O
,	O
58	O
-	O
182	O
37007	O
Salamanca	O
Spain	O
María	O
Victoria	O
Mateos	O
María	O
Victoria	O
Mateos	O
María	O
Victoria	O
Mateos	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
[P1]	O
plitidepsin	O
[P2]	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
25	O
June	O
2019	O
10.1007	O
/	O
s00277	O
-	O
019	O
-	O
03739	O
-	O
2	O
Received	O
:	O

Spain	O
Paseo	O
de	O
San	O
Vicente	O
,	O
58	O
-	O
182	O
37007	O
Salamanca	O
Spain	O
María	O
Victoria	O
Mateos	O
María	O
Victoria	O
Mateos	O
María	O
Victoria	O
Mateos	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
[P1]	O
dexamethasone	O
[P2]	O
vs.	O
dexamethasone	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
25	O
June	O
2019	O
10.1007	O
/	O
s00277	O
-	O
019	O
-	O
03739	O
-	O
2	O
Received	O
:	O

Spain	O
Paseo	O
de	O
San	O
Vicente	O
,	O
58	O
-	O
182	O
37007	O
Salamanca	O
Spain	O
María	O
Victoria	O
Mateos	O
María	O
Victoria	O
Mateos	O
María	O
Victoria	O
Mateos	O
Randomized	O
phase	O
III	O
study	O
(	O
ADMYRE	O
)	O
of	O
plitidepsin	O
in	O
combination	O
with	O
dexamethasone	O
vs.	O
[P1]	O
dexamethasone	O
[P2]	O
alone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
25	O
June	O
2019	O
25	O
June	O
2019	O
25	O
June	O
2019	O
10.1007	O
/	O
s00277	O
-	O
019	O
-	O
03739	O
-	O
2	O
Received	O
:	O

In	O
vivo	O
studies	O
showed	O
an	O
antitumour	O
effect	O
of	O
plitidepsin	O
in	O
xenograft	O
MM	O
models	O
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
dexamethasone	O
(	O
[P1]	O
DXM	O
[P2]	O
)	O
[	O
6	O
]	O
.	O

Plitidepsin	O
plus	O
[P1]	O
DXM	O
[P2]	O
showed	O
activity	O
in	O
a	O
phase	O
II	O
clinical	O
trial	O
conducted	O
in	O
relapsed	O
/	O
refractory	O
MM	O
patients	O
[	O
8	O
]	O
.	O

Based	O
on	O
the	O
data	O
from	O
the	O
randomized	O
phase	O
III	O
ADMYRE	O
trial	O
,	O
which	O
compared	O
[P1]	O
plitidepsin	O
[P2]	O
plus	O
DXM	O
with	O
DXM	O
alone	O
,	O
this	O
plitidepsin	O
combination	O
has	O
been	O
recently	O
approved	O
in	O
Australia	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
relapsed	O
/	O
refractory	O
MM	O
who	O
have	O
received	O
at	O
least	O
three	O
prior	O
treatment	O
regimens	O
,	O
including	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
Plitidepsin	O
plus	O
DXM	O
has	O
been	O
also	O
approved	O
for	O
its	O
use	O
after	O
two	O
prior	O
lines	O
of	O
therapy	O
in	O
the	O
case	O
of	O
patients	O
refractory	O
and/or	O
intolerant	O
to	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
Efficacy	O
and	O
safety	O
results	O
from	O
the	O
ADMYRE	O
trial	O
are	O
presented	O
here	O
.	O

Based	O
on	O
the	O
data	O
from	O
the	O
randomized	O
phase	O
III	O
ADMYRE	O
trial	O
,	O
which	O
compared	O
plitidepsin	O
plus	O
DXM	O
with	O
[P1]	O
DXM	O
[P2]	O
alone	O
,	O
this	O
plitidepsin	O
combination	O
has	O
been	O
recently	O
approved	O
in	O
Australia	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
relapsed	O
/	O
refractory	O
MM	O
who	O
have	O
received	O
at	O
least	O
three	O
prior	O
treatment	O
regimens	O
,	O
including	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
Plitidepsin	O
plus	O
DXM	O
has	O
been	O
also	O
approved	O
for	O
its	O
use	O
after	O
two	O
prior	O
lines	O
of	O
therapy	O
in	O
the	O
case	O
of	O
patients	O
refractory	O
and/or	O
intolerant	O
to	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
Efficacy	O
and	O
safety	O
results	O
from	O
the	O
ADMYRE	O
trial	O
are	O
presented	O
here	O
.	O

Based	O
on	O
the	O
data	O
from	O
the	O
randomized	O
phase	O
III	O
ADMYRE	O
trial	O
,	O
which	O
compared	O
plitidepsin	O
plus	O
DXM	O
with	O
DXM	O
alone	O
,	O
this	O
[P1]	O
plitidepsin	O
[P2]	O
combination	O
has	O
been	O
recently	O
approved	O
in	O
Australia	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
relapsed	O
/	O
refractory	O
MM	O
who	O
have	O
received	O
at	O
least	O
three	O
prior	O
treatment	O
regimens	O
,	O
including	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
Plitidepsin	O
plus	O
DXM	O
has	O
been	O
also	O
approved	O
for	O
its	O
use	O
after	O
two	O
prior	O
lines	O
of	O
therapy	O
in	O
the	O
case	O
of	O
patients	O
refractory	O
and/or	O
intolerant	O
to	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
Efficacy	O
and	O
safety	O
results	O
from	O
the	O
ADMYRE	O
trial	O
are	O
presented	O
here	O
.	O

Based	O
on	O
the	O
data	O
from	O
the	O
randomized	O
phase	O
III	O
ADMYRE	O
trial	O
,	O
which	O
compared	O
plitidepsin	O
plus	O
DXM	O
with	O
DXM	O
alone	O
,	O
this	O
plitidepsin	O
combination	O
has	O
been	O
recently	O
approved	O
in	O
Australia	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
relapsed	O
/	O
refractory	O
MM	O
who	O
have	O
received	O
at	O
least	O
three	O
prior	O
treatment	O
regimens	O
,	O
including	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
[P1]	O
Plitidepsin	O
[P2]	O
plus	O
DXM	O
has	O
been	O
also	O
approved	O
for	O
its	O
use	O
after	O
two	O
prior	O
lines	O
of	O
therapy	O
in	O
the	O
case	O
of	O
patients	O
refractory	O
and/or	O
intolerant	O
to	O
both	O
a	O
PI	O
and	O
an	O
IMiD.	O
Efficacy	O
and	O
safety	O
results	O
from	O
the	O
ADMYRE	O
trial	O
are	O
presented	O
here	O
.	O

On	O
this	O
basis	O
,	O
the	O
choice	O
of	O
the	O
[P1]	O
control	O
arm	O
[P2]	O
(	O
low	O
-	O
dose	O
DXM	O
)	O
was	O
agreed	O
with	O
the	O
health	O
authorities	O
(	O
European	O
Medicines	O
Agency	O
and	O
Food	O
and	O
Drug	O
Administration	O
of	O
the	O
USA	O
)	O
.	O

On	O
this	O
basis	O
,	O
the	O
choice	O
of	O
the	O
control	O
arm	O
(	O
[P1]	O
low	O
-	O
dose	O
DXM	O
[P2]	O
)	O
was	O
agreed	O
with	O
the	O
health	O
authorities	O
(	O
European	O
Medicines	O
Agency	O
and	O
Food	O
and	O
Drug	O
Administration	O
of	O
the	O
USA	O
)	O
.	O

Patients	O
were	O
stratified	O
according	O
to	O
their	O
ECOG	O
PS	O
score	O
(	O
0	O
and	O
1	O
vs.	O
2	O
)	O
and	O
Durie	O
-	O
Salmon	O
stage	O
(	O
I	O
/	O
II	O
vs.	O
III	O
)	O
and	O
were	O
randomly	O
assigned	O
(	O
with	O
a	O
2:1	O
ratio	O
)	O
to	O
receive	O
[P1]	O
plitidepsin	O
[P2]	O
5	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
on	O
D1	O
and	O
D15	O
intravenously	O
(	O
i.v	O
.	O
)	O

over	O
3	O
h	O
plus	O
[P1]	O
DXM	O
[P2]	O
40	B-arm_dosage
mg	I-arm_dosage
orally	O
on	O
D1	O
,	O
D8	O
,	O
D15	O
,	O
and	O
D22	O
(	O
arm	O
A	O
)	O
or	O
DXM	O
40	O
mg	O
orally	O
on	O
D1	O
,	O
D8	O
,	O
D15	O
,	O
and	O
D22	O
(	O
arm	O
B	O
)	O
,	O
every	O
4	O
weeks	O
(	O
q4wk	O
)	O
.	O

over	O
3	O
h	O
plus	O
DXM	O
40	O
mg	O
orally	O
on	O
D1	O
,	O
D8	O
,	O
D15	O
,	O
and	O
D22	O
(	O
arm	O
A	O
)	O
or	O
[P1]	O
DXM	O
[P2]	O
40	B-arm_dosage
mg	I-arm_dosage
orally	O
on	O
D1	O
,	O
D8	O
,	O
D15	O
,	O
and	O
D22	O
(	O
arm	O
B	O
)	O
,	O
every	B-arm_dosage
4	I-arm_dosage
weeks	I-arm_dosage
(	O
q4wk	O
)	O
.	O

Patients	O
in	O
the	O
control	O
arm	O
(	O
[P1]	O
DXM	O
[P2]	O
alone	O
,	O
arm	O
B	O
)	O
with	O
documented	O
disease	O
progression	O
after	O
a	O
minimum	O
of	O
8	O
weeks	O
from	O
randomization	O
could	O
crossover	O
to	O
the	O
combination	O
arm	O
(	O
arm	O
A	O
)	O
.	O

Patients	O
in	O
the	O
control	O
arm	O
(	O
DXM	O
alone	O
,	O
[P1]	O
arm	O
B	O
[P2]	O
)	O
with	O
documented	O
disease	O
progression	O
after	O
a	O
minimum	O
of	O
8	O
weeks	O
from	O
randomization	O
could	O
crossover	O
to	O
the	O
combination	O
arm	O
(	O
arm	O
A	O
)	O
.	O

Follow	O
-	O
up	O
was	O
longer	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
partly	O
because	O
it	O
included	O
patients	O
that	O
had	O
crossed	O
over	O
from	O
arm	O
B.	O

Follow	O
-	O
up	O
was	O
longer	O
in	O
arm	O
A	O
partly	O
because	O
it	O
included	O
patients	O
that	O
had	O
crossed	O
over	O
from	O
[P1]	O
arm	O
B.	O
[P2]	O

A	O
futility	O
analysis	O
was	O
done	O
once	O
40	O
patients	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
were	O
evaluable	O
for	O
response	O
.	O

44.0	O
%	O
of	O
patients	O
from	O
[P1]	O
arm	O
B	O
[P2]	O
crossed	O
over	O
to	O
arm	O
A	O
(	O
Fig	O
.	O

44.0	O
%	O
of	O
patients	O
from	O
arm	O
B	O
crossed	O
over	O
to	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
Fig	O
.	O

171	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
and	O
84	O
in	O
arm	O
B.	O
Of	O
these	O
,	O
167	O
patients	O
were	O
treated	O
in	O
arm	O
A	O
and	O
83	O
in	O
arm	O
B	O
(	O
Fig	O
.	O

171	O
in	O
arm	O
A	O
and	O
84	O
in	O
[P1]	O
arm	O
B.	O
[P2]	O
Of	O
these	O
,	O
167	O
patients	O
were	O
treated	O
in	O
arm	O
A	O
and	O
83	O
in	O
arm	O
B	O
(	O
Fig	O
.	O

171	O
in	O
arm	O
A	O
and	O
84	O
in	O
arm	O
B.	O
Of	O
these	O
,	O
167	O
patients	O
were	O
treated	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
and	O
83	O
in	O
arm	O
B	O
(	O
Fig	O
.	O

171	O
in	O
arm	O
A	O
and	O
84	O
in	O
arm	O
B.	O
Of	O
these	O
,	O
167	O
patients	O
were	O
treated	O
in	O
arm	O
A	O
and	O
83	O
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
Fig	O
.	O

The	O
primary	O
efficacy	O
analysis	O
,	O
with	O
blinded	O
IRC	O
assessment	O
of	O
all	O
randomized	O
patients	O
done	O
without	O
PD	O
confirmation	O
,	O
showed	O
statistically	O
significant	O
longer	O
PFS	O
for	O
patients	O
treated	O
with	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
.	O

Median	O
PFS	O
was	O
2.6	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.9	I-arm_efficacy_results
-	I-arm_efficacy_results
3.0	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
1.7	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
2.0	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0054	O
)	O
(	O
Fig	O
.	O

Median	O
PFS	O
was	O
2.6	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.9	I-arm_efficacy_results
-	I-arm_efficacy_results
3.0	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
and	O
1.7	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
2.0	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0054	O
)	O
(	O
Fig	O
.	O

Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
2.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.9	O
-	O
3.0	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
1.7	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.1	I-arm_efficacy_results
-	I-arm_efficacy_results
2.0	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0054	O
)	O
(	O
Fig	O
.	O

Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
was	O
2.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.9	O
-	O
3.0	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
1.7	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.1	I-arm_efficacy_results
-	I-arm_efficacy_results
2.0	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0054	O
)	O
(	O
Fig	O
.	O

The	O
relative	O
risk	O
of	O
progression	O
or	O
death	O
was	O
reduced	O
by	O
35.0	O
%	O
in	O
patients	O
treated	O
with	O
Relapsed	O
MM	O
was	O
defined	O
as	O
previously	O
treated	O
myeloma	O
that	O
progressed	O
and	O
required	O
the	O
initiation	O
of	O
salvage	O
therapy	O
but	O
did	O
not	O
meet	O
the	O
criteria	O
for	O
either	O
"	O
refractory	O
"	O
or	O
"	O
relapsed	O
and	O
refractory	O
"	O
myeloma	O
categories	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
(	O
HR	O
=	O
0.650	O
;	O

PFS	O
analysis	O
requiring	O
PD	O
confirmation	O
by	O
an	O
investigator	O
's	O
assessment	O
showed	O
a	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
3.8	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
2.9	I-arm_efficacy_results
-	I-arm_efficacy_results
5.6	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
1.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
2.7	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
,	O
with	O
a	O
relative	O
risk	O
of	O
progression	O
or	O
death	O
reduced	O
by	O
38.9	O
%	O
in	O
patients	O
treated	O
with	O
plitidepsin	O
plus	O
DXM	O
(	B-arm_efficacy_results
HR	I-arm_efficacy_results
=	I-arm_efficacy_results
0.611	I-arm_efficacy_results
;	I-arm_efficacy_results

PFS	O
analysis	O
requiring	O
PD	O
confirmation	O
by	O
an	O
investigator	O
's	O
assessment	O
showed	O
a	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
3.8	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
2.9	I-arm_efficacy_results
-	I-arm_efficacy_results
5.6	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
and	O
1.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
2.7	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
,	O
with	O
a	O
relative	O
risk	O
of	O
progression	O
or	O
death	O
reduced	O
by	O
38.9	O
%	O
in	O
patients	O
treated	O
with	O
plitidepsin	O
plus	O
DXM	O
(	B-arm_efficacy_results
HR	I-arm_efficacy_results
=	I-arm_efficacy_results
0.611	I-arm_efficacy_results
;	I-arm_efficacy_results

PFS	B-arm_efficacy_metric
analysis	O
requiring	O
PD	O
confirmation	O
by	O
an	O
investigator	O
's	O
assessment	O
showed	O
a	O
median	O
PFS	O
of	O
3.8	O
months	O
(	O
95	O
%	O
CI	O
,	O
2.9	O
-	O
5.6	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
1.9	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.1	I-arm_efficacy_results
-	I-arm_efficacy_results
2.7	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
)	O
,	O
with	O
a	O
relative	O
risk	O
of	O
progression	O
or	O
death	O
reduced	O
by	O
38.9	O
%	O
in	O
patients	O
treated	O
with	O
plitidepsin	O
plus	O
DXM	O
(	O
HR	O
=	O
0.611	O
;	O

PFS	B-arm_efficacy_metric
analysis	O
requiring	O
PD	O
confirmation	O
by	O
an	O
investigator	O
's	O
assessment	O
showed	O
a	O
median	O
PFS	O
of	O
3.8	O
months	O
(	O
95	O
%	O
CI	O
,	O
2.9	O
-	O
5.6	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
1.9	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
1.1	I-arm_efficacy_results
-	I-arm_efficacy_results
2.7	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
)	O
,	O
with	O
a	O
relative	O
risk	O
of	O
progression	O
or	O
death	O
reduced	O
by	O
38.9	O
%	O
in	O
patients	O
treated	O
with	O
plitidepsin	O
plus	O
DXM	O
(	O
HR	O
=	O
0.611	O
;	O

PFS	O
analysis	O
requiring	O
PD	O
confirmation	O
by	O
an	O
investigator	O
's	O
assessment	O
showed	O
a	O
median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
of	O
3.8	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
,	I-arm_efficacy_results
2.9	I-arm_efficacy_results
-	I-arm_efficacy_results
5.6	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
1.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
1.1	O
-	O
2.7	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
,	O
with	O
a	O
relative	O
risk	O
of	O
progression	O
or	O
death	O
reduced	O
by	O
38.9	O
%	O
in	O
patients	O
treated	O
with	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
(	B-arm_efficacy_results
HR	I-arm_efficacy_results
=	I-arm_efficacy_results
0.611	I-arm_efficacy_results
;	I-arm_efficacy_results

ORR	O
according	O
to	O
the	O
IRC	O
in	O
evaluable	O
patients	O
was	O
13.8	O
%	O
(	O
95	O
%	O
CI	O
,	O
8.3	O
-	O
21.2	O
%	O
)	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
;	O

ORR	O
according	O
to	O
the	O
IRC	O
in	O
evaluable	O
patients	O
was	O
13.8	O
%	O
(	O
95	O
%	O
CI	O
,	O
8.3	O
-	O
21.2	O
%	O
)	O
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
[P2]	O
plus	O
DXM	O
;	O

ORR	O
according	O
to	O
the	O
IRC	O
in	O
evaluable	O
patients	O
was	O
13.8	O
%	O
(	O
95	O
%	O
CI	O
,	O
8.3	O
-	O
21.2	O
%	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
[P1]	O
DXM	O
[P2]	O
;	O

n	O
=	O
123	O
)	O
,	O
which	O
included	O
two	O
very	O
good	O
partial	O
responses	O
and	O
15	O
partial	O
responses	O
(	O
median	O
duration	O
of	O
response	O
was	O
12.0	O
months	O
)	O
,	O
and	O
1.7	O
%	O
(	O
95	O
%	O
CI	O
,	O
0.04	O
-	O
9.1	O
%	O
)	O
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
;	O

n	O
=	O
123	O
)	O
,	O
which	O
included	O
two	O
very	O
good	O
partial	O
responses	O
and	O
15	O
partial	O
responses	O
(	O
median	O
duration	O
of	O
response	O
was	O
12.0	O
months	O
)	O
,	O
and	O
1.7	O
%	O
(	O
95	O
%	O
CI	O
,	O
0.04	O
-	O
9.1	O
%	O
)	O
in	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
;	O

The	O
clinical	O
benefit	O
rate	O
,	O
defined	O
as	O
patients	O
with	O
response	O
(	O
including	O
MR	O
)	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
was	O
48.0	O
%	O
(	O
95	O
%	O
CI	O
,	O
40.3	O
-	O
55.7	O
%	O
)	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
28.6	O
%	O
(	O
95	O
%	O
CI	O
,	O
19.2	O
-	O
39.5	O
%	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
p	O
<	O
0.0044	O
)	O
.	O

The	O
clinical	O
benefit	O
rate	O
,	O
defined	O
as	O
patients	O
with	O
response	O
(	O
including	O
MR	O
)	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
was	O
48.0	O
%	O
(	O
95	O
%	O
CI	O
,	O
40.3	O
-	O
55.7	O
%	O
)	O
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
and	O
28.6	O
%	O
(	O
95	O
%	O
CI	O
,	O
19.2	O
-	O
39.5	O
%	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
p	O
<	O
0.0044	O
)	O
.	O

The	O
clinical	O
benefit	O
rate	O
,	O
defined	O
as	O
patients	O
with	O
response	O
(	O
including	O
MR	O
)	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
was	O
48.0	O
%	O
(	O
95	O
%	O
CI	O
,	O
40.3	O
-	O
55.7	O
%	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
28.6	O
%	O
(	O
95	O
%	O
CI	O
,	O
19.2	O
-	O
39.5	O
%	O
)	O
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
)	O
(	O
p	O
<	O
0.0044	O
)	O
.	O

The	O
clinical	O
benefit	O
rate	O
,	O
defined	O
as	O
patients	O
with	O
response	O
(	O
including	O
MR	O
)	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
was	O
48.0	O
%	O
(	O
95	O
%	O
CI	O
,	O
40.3	O
-	O
55.7	O
%	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
28.6	O
%	O
(	O
95	O
%	O
CI	O
,	O
19.2	O
-	O
39.5	O
%	O
)	O
in	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
)	O
(	O
p	O
<	O
0.0044	O
)	O
.	O

Median	O
OS	O
was	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
8.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
6.0	O
-	O
15.4	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.1261	O
)	O
(	O
Fig	O
.	O

Median	O
OS	O
was	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
and	O
8.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
6.0	O
-	O
15.4	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.1261	O
)	O
(	O
Fig	O
.	O

Median	O
OS	O
was	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
8.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
6.0	O
-	O
15.4	O
months	O
)	O
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.1261	O
)	O
(	O
Fig	O
.	O

Median	O
OS	O
was	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
8.9	O
months	O
(	O
95	O
%	O
CI	O
,	O
6.0	O
-	O
15.4	O
months	O
)	O
in	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.1261	O
)	O
(	O
Fig	O
.	O

Despite	O
crossover	O
,	O
relative	O
risk	O
of	O
death	O
was	O
reduced	O
by	O
20.3	O
%	O
in	O
patients	O
treated	O
with	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
(	O
HR	O
=	O
0.797	O
;	O

Median	O
OS	O
for	O
patients	O
with	O
response	O
or	O
clinical	O
benefit	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
was	O
37.8	O
months	O
and	O
30.3	O
months	O
,	O
respectively	O
(	O
Fig	O
.	O

Median	O
OS	O
for	O
patients	O
with	O
response	O
or	O
clinical	O
benefit	O
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
was	O
37.8	O
months	O
and	O
30.3	O
months	O
,	O
respectively	O
(	O
Fig	O
.	O

A	O
two	O
-	O
stage	O
OS	O
analysis	O
,	O
which	O
mitigates	O
the	O
effect	O
of	O
crossover	O
,	O
showed	O
a	O
statistically	O
significant	O
difference	O
in	O
favor	O
of	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
.	O

A	O
two	O
-	O
stage	O
OS	O
analysis	O
,	O
which	O
mitigates	O
the	O
effect	O
of	O
crossover	O
,	O
showed	O
a	O
statistically	O
significant	O
difference	O
in	O
favor	O
of	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
.	O

Median	O
OS	O
remained	O
as	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
was	O
estimated	O
as	O
6.4	O
months	O
(	O
95	O
%	O
CI	O
,	O
5.1	O
-	O
8.3	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0015	O
)	O
(	O
Fig	O
.	O

Median	O
OS	O
remained	O
as	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
and	O
was	O
estimated	O
as	O
6.4	O
months	O
(	O
95	O
%	O
CI	O
,	O
5.1	O
-	O
8.3	O
months	O
)	O
in	O
arm	O
B	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0015	O
)	O
(	O
Fig	O
.	O

Median	O
OS	O
remained	O
as	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
was	O
estimated	O
as	O
6.4	O
months	O
(	O
95	O
%	O
CI	O
,	O
5.1	O
-	O
8.3	O
months	O
)	O
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0015	O
)	O
(	O
Fig	O
.	O

Median	O
OS	O
remained	O
as	O
11.6	O
months	O
(	O
95	O
%	O
CI	O
,	O
9.2	O
-	O
16.1	O
months	O
)	O
in	O
arm	O
A	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
and	O
was	O
estimated	O
as	O
6.4	O
months	O
(	O
95	O
%	O
CI	O
,	O
5.1	O
-	O
8.3	O
months	O
)	O
in	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
)	O
(	O
log	O
-	O
rank	O
p	O
=	O
0.0015	O
)	O
(	O
Fig	O
.	O

Relative	O
risk	O
of	O
death	O
was	O
reduced	O
by	O
37.8	O
%	O
in	O
patients	O
treated	O
with	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
(	O
HR	O
=	O
0.622	O
;	O

The	O
median	O
(	O
range	O
)	O
of	O
cycles	O
received	O
was	O
3	O
(	O
1	O
-	O
33	O
)	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
;	O

The	O
median	O
(	O
range	O
)	O
of	O
cycles	O
received	O
was	O
3	O
(	O
1	O
-	O
33	O
)	O
in	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
;	O

total	O
cycles	O
=	O
842	O
)	O
and	O
2	O
(	O
1	O
-	O
21	O
)	O
in	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
;	O

total	O
cycles	O
=	O
842	O
)	O
and	O
2	O
(	O
1	O
-	O
21	O
)	O
in	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
;	O

Median	O
time	O
on	O
treatment	O
was	O
12.3	O
weeks	O
(	O
1.3	O
-	O
137.1	O
weeks	O
)	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
and	O
8.3	O
weeks	O
(	O
1.4	O
-	O
85.3	O
weeks	O
)	O
in	O
arm	O
B.	O
Fifteen	O
patients	O
(	O
9.0	O
%	O
)	O
discontinued	O
treatment	O
because	O
of	O
treatment	O
-	O
related	O
AEs	O
in	O
arm	O
A	O
and	O
eight	O
patients	O
(	O
9.6	O
%	O
)	O
in	O
arm	O
B.	O

Median	O
time	O
on	O
treatment	O
was	O
12.3	O
weeks	O
(	O
1.3	O
-	O
137.1	O
weeks	O
)	O
in	O
arm	O
A	O
and	O
8.3	O
weeks	O
(	O
1.4	O
-	O
85.3	O
weeks	O
)	O
in	O
[P1]	O
arm	O
B.	O
[P2]	O
Fifteen	O
patients	O
(	O
9.0	O
%	O
)	O
discontinued	O
treatment	O
because	O
of	O
treatment	O
-	O
related	O
AEs	O
in	O
arm	O
A	O
and	O
eight	O
patients	O
(	O
9.6	O
%	O
)	O
in	O
arm	O
B.	O

Median	O
time	O
on	O
treatment	O
was	O
12.3	O
weeks	O
(	O
1.3	O
-	O
137.1	O
weeks	O
)	O
in	O
arm	O
A	O
and	O
8.3	O
weeks	O
(	O
1.4	O
-	O
85.3	O
weeks	O
)	O
in	O
arm	O
B.	O
Fifteen	O
patients	O
(	O
9.0	O
%	O
)	O
discontinued	O
treatment	O
because	O
of	O
treatment	O
-	O
related	O
AEs	O
in	O
[P1]	O
arm	O
A	O
[P2]	O
and	O
eight	O
patients	O
(	O
9.6	O
%	O
)	O
in	O
arm	O
B.	O

Median	O
time	O
on	O
treatment	O
was	O
12.3	O
weeks	O
(	O
1.3	O
-	O
137.1	O
weeks	O
)	O
in	O
arm	O
A	O
and	O
8.3	O
weeks	O
(	O
1.4	O
-	O
85.3	O
weeks	O
)	O
in	O
arm	O
B.	O
Fifteen	O
patients	O
(	O
9.0	O
%	O
)	O
discontinued	O
treatment	O
because	O
of	O
treatment	O
-	O
related	O
AEs	O
in	O
arm	O
A	O
and	O
eight	O
patients	O
(	O
9.6	O
%	O
)	O
in	O
[P1]	O
arm	O
B.	O
[P2]	O

In	O
[P1]	O
arm	O
A	O
[P2]	O
(	O
plitidepsin	O
plus	O
DXM	O
)	O
,	O
the	O
most	O
common	O
AEs	O
(	O
all	O
grades	O
)	O
related	O
to	O
the	O
study	O
treatment	O
(	O
or	O
with	O
unknown	O
causality	O
)	O
were	O
nausea	O
(	O
37.1	O
%	O
of	O
patients	O
)	O
,	O
fatigue	O
(	O
36.5	O
%	O
)	O
,	O
vomiting	O
(	O
16.8	O
%	O
)	O
,	O
diarrhea	O
(	O
14.4	O
%	O
)	O
,	O
myalgia	O
(	O
14.4	O
%	O
)	O
,	O
peripheral	O
edema	O
(	O
12.0	O
%	O
)	O
,	O
decreased	O
appetite	O
(	O
12.6	O
%	O
)	O
,	O
and	O
Table	O
2	O
)	O
.	O

In	O
arm	O
A	O
(	O
[P1]	O
plitidepsin	O
plus	O
DXM	O
[P2]	O
)	O
,	O
the	O
most	O
common	O
AEs	O
(	O
all	O
grades	O
)	O
related	O
to	O
the	O
study	O
treatment	O
(	O
or	O
with	O
unknown	O
causality	O
)	O
were	O
nausea	O
(	O
37.1	O
%	O
of	O
patients	O
)	O
,	O
fatigue	O
(	O
36.5	O
%	O
)	O
,	O
vomiting	O
(	O
16.8	O
%	O
)	O
,	O
diarrhea	O
(	O
14.4	O
%	O
)	O
,	O
myalgia	O
(	O
14.4	O
%	O
)	O
,	O
peripheral	O
edema	O
(	O
12.0	O
%	O
)	O
,	O
decreased	O
appetite	O
(	O
12.6	O
%	O
)	O
,	O
and	O
Table	O
2	O
)	O
.	O

In	O
[P1]	O
arm	O
B	O
[P2]	O
(	O
DXM	O
)	O
,	O
the	O
most	O
common	O
AEs	O
(	O
all	O
grades	O
)	O
related	O
to	O
the	O
study	O
treatment	O
(	O
or	O
with	O
unknown	O
causality	O
)	O
were	O
nausea	O
(	O
10.8	O
%	O
)	O
,	O
fatigue	O
(	O
8.4	O
%	O
)	O
,	O
and	O
insomnia	O
(	O
9.6	O
%	O
)	O
.	O

In	O
arm	O
B	O
(	O
[P1]	O
DXM	O
[P2]	O
)	O
,	O
the	O
most	O
common	O
AEs	O
(	O
all	O
grades	O
)	O
related	O
to	O
the	O
study	O
treatment	O
(	O
or	O
with	O
unknown	O
causality	O
)	O
were	O
nausea	O
(	O
10.8	O
%	O
)	O
,	O
fatigue	O
(	O
8.4	O
%	O
)	O
,	O
and	O
insomnia	O
(	O
9.6	O
%	O
)	O
.	O